P023 | GLOBAL DYSREGULATION OF THE SPECIALIZED PRO-RESOLVING MEDIATOR NETWORK IN PERIPHERAL MACROPHAGES OF PD PATIENTS WITH AND WITHOUT GBA1 MUTATIONS
Objectives. Neuroinflammation is a recognized pathological hallmark of Parkinson’s disease (PD). Heterozygous mutations in the GBA1 gene represent the most frequent genetic risk factor for PD. PD carriers of GBA1 mutations (GBA‐PD) progress more rapidly, with earlier cognitive dysfunction and psychosis, greater substantia nigra terminal loss, and reduced survival 1-2. While chronic activation of the innate immune system is well established in neurodegeneration, the mechanisms governing the "resolution of inflammation" – an active process driven by endogenous polyunsaturated lipids called Specialized Pro-resolving Mediators (SPMs) – remain largely unexplored in peripheral immune cells of PD patients3. Our aim, therefore, is to characterize the protein expression profiles of key SPM receptors (GPR18, GPR32, ChemR23, FPR2) and biosynthetic enzymes (15-PGDH, 15-LOX, 12-LOX, 5-LOX) in classically activated macrophages (M1-like) and alternatively activated macrophages (M2-like) across idiopathic PD, GBA-mutated PD and healthy controls. Methods. Peripheral blood mononuclear cells were isolated from patients and monocytes were differentiated into macrophages M1- and M2-like. Target protein expression was quantified via flow cytometry using Mean Fluorescence Intensity (MFI). Group segregation and key driving biomarkers were identified using univariate statistics and multivariate Partial Least Squares-Discriminant Analysis (PLS-DA) with Variable Importance in Projection (VIP) scores. The phagocytic capacity of the macrophages in all experimental groups was assessed using the efferocytosis assay. Results. Multivariate PLS-DA effectively separated the clinical groups from healthy controls, identifying 12-LOX, ChemR23 and 15-LOX as the top driving features. In macrophages M1-like, a significant downregulation of the pro-resolving receptor ChemR23 was observed in both PD and PD-GBA groups compared to controls, accompanied by an upregulated expression trend for the GPR32 receptor in idiopathic PD cases and a significant upregulation of the 12-LOX enzyme that was particularly pronounced in the PD-GBA cohort. At the same time, in M2-like macrophages, which are crucial for tissue repair and homeostasis, multivariate PLS-DA identifies ChemR23, FPR2, and the enzyme 5-LOX as the most significant discriminating biomarkers. In particular, there is a significant reduction in the expression of both pro-resolving receptors ChemR23 and FPR2 compared to controls, alongside a marked downregulation trend for GPR18 in sporadic PD. The efferocytosis assay revealed a reduced phagocytic capacity in PD macrophages compared with the controls. Conclusions. Our results highlight a global alteration of the resolution of inflammation process in Parkinson’s disease. Particular attention centers on macrophages, the key players; which in both M1- and M2-like states, and across both idiopathic PD and PD-GBA groups, showed a dysregulated expression of SPM receptors and biosynthetic enzymes compared to healthy controls. This systemic imbalance may fail to counteract chronic inflammation, thereby contributing to neurodegeneration.
Authors
- Movement Disorders Service
Institutions
- Centre National de la Recherche Scientifique (FR)
- Università Campus Bio-Medico (IT)
- Laboratoire d'Informatique de Grenoble (FR)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- European Journal of Histochemistry
- Published
- 2026-11-20
- DOI
- https://doi.org/10.4081/ejh.2026.4843
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00